Since the development of innovative therapy techniques, medications in the SGLT2-i class, such as dapagliflozin, when administered at a dose of 10 mg once daily in symptomatic heart failure have decreased mortality, improved quality of life, and increased life expectancy. The gene discussed is SLC5A2; the disease is heart failure.